Acamprosate Titration
Acamprosate requires no titration—it is started at full therapeutic dose immediately. 1
Standard Dosing Protocol
The recommended dose is 666 mg (two 333 mg tablets) three times daily, started on day one of treatment, with no gradual increase required. 1 This differs fundamentally from medications like gabapentin or allopurinol that require slow titration over weeks 2, 3.
Weight-Based Adjustments
- Patients ≥60 kg: 666 mg three times daily (1,998 mg total daily dose) 4, 1
- Patients <60 kg: Reduce dose by one-third to 1,332 mg daily 4, 5
Renal Function Adjustments
- Moderate renal impairment (CrCl 30-50 mL/min): Start at 333 mg three times daily 1
- Severe renal impairment (CrCl ≤30 mL/min): Contraindicated 1
Critical Timing Considerations
Acamprosate must be initiated 3-7 days after the last alcohol consumption and only after withdrawal symptoms have completely resolved. 4, 5, 1 This is a common pitfall—starting too early reduces efficacy because acamprosate maintains abstinence rather than induces it 5, 6.
Practical Algorithm for Initiation
- Complete alcohol detoxification (e.g., benzodiazepine taper with chlordiazepoxide/Librium) 5
- Wait 3-7 days after last alcohol consumption 5, 1
- Confirm withdrawal symptoms have resolved 5
- Start full therapeutic dose immediately—no titration period 1
- Continue for minimum 3-6 months, up to 12 months 4, 5
Pharmacokinetic Rationale
Steady-state plasma concentrations are reached within 5-7 days of starting the full dose, with no need for gradual escalation. 4, 7 The drug demonstrates time- and dose-independent pharmacokinetics with an accumulation ratio of approximately 2.4 at steady-state 7. The terminal elimination half-life after oral administration is approximately 30 hours due to flip-flop kinetics from the enteric-coated formulation 7.
Evidence for Immediate Full Dosing
The landmark efficacy trials used immediate full-dose initiation without titration 8, 9. In the largest placebo-controlled trial of 455 patients, acamprosate 1,998 mg daily (or 1,332 mg for patients ≤60 kg) was started immediately after detoxification, resulting in 18.3% continuous abstinence versus 7.1% with placebo at 360 days (p=0.007) 8. Network meta-analysis confirmed acamprosate's efficacy with odds ratio 1.86 for abstinence versus placebo 10.
Common Pitfalls to Avoid
- Starting during active withdrawal: Acamprosate does not treat withdrawal and will be ineffective if started too early 4, 5
- Attempting gradual titration: This is unnecessary and delays achievement of therapeutic levels 1, 7
- Discontinuing for mild diarrhea: Gastrointestinal side effects (primarily diarrhea) are usually mild and transient 6, 8
- Using without psychosocial support: Acamprosate should always be combined with comprehensive psychosocial treatment programs 1, 6
Safety Advantages
Acamprosate carries no risk of hepatotoxicity, making it the preferred agent for patients with alcohol-associated liver disease. 4 Unlike naltrexone (contraindicated in liver disease) and disulfiram (avoided in severe liver disease), acamprosate is not metabolized by the liver and requires no dose adjustment for hepatic impairment 5, 7.